BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

DVC Deutsche Venture Capital strengthens its management team in the technology field

19th March 2004 Munich – DVC Deutsche Venture Capital, one of Europe’s leading venture capital companies based in Munich, strengthens its technology team with the appointment of Bernhard Schmid, former technology expert at Innotech.

Bernhard Schmid strengthens DVC’s tech team as partner as of March 2004. He brings ten years of experience in information and communication technology to the activities of the internationally renowned venture capital company. Prior to joining DVC he was (from 1999 up until 2004) partner and technology expert at the venture capital company Innotech GmbH. From 1994 to 1999 he worked as an investment manager for Atlas Venture, a globally active venture capital company, where he was in charge of investments as well as portfolio and exit management for information and communication technology companies.

In addition to supporting existing portfolio companies, Bernhard Schmid’s principal role at DVC is to consist in reinforcing new investments in technological companies with an emphasis on information and communication technologies. He holds a degree in business administration from the Ludwig Maximilians University in Munich.

“With the continued expansion of our highly skilled and experienced technology team we are now in a position to provide young companies with more comprehensive and greater expert support”, comments Dr. Joerg Neermann, Managing Partner of DVC. “I’m very much looking forward to working with DVC’s professional and VC experienced tech team”, adds Mr. Schmid, “as well as to interesting projects and to the challenges that lie ahead.”

DVC Deutsche Venture Capital, a leading venture capitalist based in Munich, focuses primarily on European growth companies in the areas of information, telecommunication, semiconductor and industrial technologies as well as life sciences. In the field of life sciences DVC invests in the development of therapeutic and diagnostic products as well as in platform and medical technologies. DVC’s total administrated fund volume amounts to 300 million Euro. For investments in private companies, DVC invests approximately 1 - 10 million Euro as lead investor or, in the case of larger financing rounds, as co-lead investor. DVC is a “value-added” financial investor. Each sector team consists of experienced investment managers with relevant backgrounds. Since its formation in 1998, DVC has invested in approximately 50 companies.

A picture of Bernhard Schmid is provided at http://www.dvcg.de/company/downloads.asp

In the event of publication please send us a copy – thank you!

Press Contact

Heidrun Moll

DVC Deutsche Venture Capital

Neumarkter Str. 28

D – 81673 München

Tel        +49 89 41 36 87 12

Fax       +49 89 41 36 87 87

heidrun.moll@dvcg.de

www.dvcg.de

 

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.